Real Life Sciences Japan to attend the 15th DIA Annual Meeting 2018

Real Life Sciences Japan will be exhibiting at DIA 2018, an event which showcases innovation and advances that are occurring in the medical industry both here in Japan and internationally.

The theme for this year is ‘Promoting Better Collaboration to Drive Global Health and Innovation in an Era of Medical and Scientific Transformation.’

Japan possesses the second largest medical industry in the world. Due to economic and demographic factors it is likely this economy will continue to expand. DIA will give attendees a chance to learn more about how Japan is going to meet this growing demand along with advancements in the industry.

DIA attracts some of the most prevalent names in the industry, we look forward to see our clients and industry partners there.  

 

What will the event cover?

AI

With an increasing number of pharma companies in Japan who are starting to venture into areas such as AI in drug discovery, health services and even medical devices, AI is a huge topic to be discussed at DIA. Furthermore, with the aging population, AI serves as a support and form of assistance to ease the burden in shortage of medical practitioners and specialists, along with other pharma manufacturers.

Big data in genomics

The ability to collect and access vast data sets, such as a patient's entire genome, has transformed the way we look at diseases, and it’s driving change across healthcare systems in Japan. What was once perceived to be time consuming and cost ineffective is now becoming increasingly manageable by connecting electronic records from hospitals, health centers and medical practices to generate, analyse and provide a portal for doctors in real time with the use of big data.

Cell and gene therapies

Japan’s rapidly aging population creates a perfect testing ground for gene therapies, and regenerative medication. The Japanese Gene Therapy Research Institution is also renowned for possessing the best capabilities in terms of talent and skills. As such, this has led to an influx of foreign partnerships, research studies, and licensing deals in the country as global companies are enticed to conduct R&D in Japan for various innovative medical products.

Currently, the sector is at the forefront in scoring research partnerships between private biotech companies and Japanese universities and is portraying a very exciting outlook for the industry in the next few years.

 

Details of the event

Venue: Tokyo Big Sight

Date: November 11-13, 2018

Booth: No.9

As the scene for healthcare product development becomes increasingly global, there is also no better time to deepen the discussion on how we can leverage on the individual strengths of countries. From promoting better collaboration, to strengthening global partnerships, Japan is on a journey to build a conducive ecosystem for creating medication, medical devices, and regenerative medical products. DIA will be an event to look forward to, that will conduct sessions on various topics mentioned above.

To get updated on the latest industry trends as well as contribute to the industry in terms of talent insights, Real Life Sciences Japan will be having a booth at this much anticipated event. If you’d like to find out more, get connected with us at con[email protected] for more updates. You may also visit our website at www.realstaffing.com for more industry related insights. For more information about the event, do also visit DIA’s Global website.

Keep a look out for more updates closer to the event and we hope to see you there! 

 

5 Professional Goals you should have for 2020

01 Jan 2020

It is the time of the year again to ponder over New Year resolutions. While various critics have suggested that only a minority of people who make resolutions stick to them, realistic and practical goals are achievable if you put your mind to it.

Are there more opportunities in South Korea’s medical scene following the government’s ₩500b investment?

10 Jul 2019

South Korea’s government spending has always played a crucial role in boosting the economy. How will this investment help in creating more jobs and encouraging innovation that can contribute to the country’s sustainable growth?

Real Life Sciences, part of SThree publishes Annual Report

03 Mar 2020

The report shows that the company’s unique position as the only pure-play, global STEM staffing specialist.

Real Life Sciences Singapore expands to Hong Kong

01 Apr 2019

Real Life Sciences Singapore – part of the larger SThree Group, has expanded to regional hubs such as Hong Kong.  Real Life Sciences has been heavily involved in the recruitment process of regional medical affairs roles for various projects led by multinational companies.